Evidence map›Paper›PMID 37445290›Full record

ArticleJournal of clinical medicine2023

Malignant Transformation and Long-Term Outcome of Oral and Laryngeal Leukoplakia.

Botond Bukovszky, János Fodor, Erika Tóth, Zsuzsa S Kocsis, Ferenc Oberna, Örs Ferenczi, Csaba Polgár

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Updates on Larynx Cancer: Risk Factors and Oncogenesis.International journal of molecular sciences · 2023
    Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Botond BukovszkyDepartment of Oncology, Semmelweis University, 1122 Budapest, Hungary.ORCID 0000-0001-6418-5719
János FodorCenter of Radiotherapy and the National Tumor Biology Laboratory, 1122 Budapest, Hungary.
Erika TóthDepartment of Surgical and Molecular Pathology and the National Tumor Biology Laboratory, 1122 Budapest, Hungary.
Zsuzsa S KocsisCenter of Radiotherapy and the National Tumor Biology Laboratory, 1122 Budapest, Hungary.
Ferenc ObernaMultidisciplinary Centre of Head and Neck Tumours and the National Tumor Biology Laboratory, 1122 Budapest, Hungary.
Örs FerencziCenter of Radiotherapy and the National Tumor Biology Laboratory, 1122 Budapest, Hungary.
Csaba PolgárDepartment of Oncology, Semmelweis University, 1122 Budapest, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOral or laryngeal leukoplakia has an increased risk for malignant transformation but the risk of the two anatomical sites has not been compared to each other yet. MATERIALS AND

methodsClinical data of 253 patients with leukoplakia (oral = 221 or laryngeal = 32) enrolled from January 1996 to January 2022 were analyzed. One hundred and seventy underwent biopsy and 83 did not. The mean follow-up time was 148.8 months. Risk factors for the malignant transformation of leukoplakia were identified using Cox proportional hazard models.

resultsIn the oral or laryngeal group, the rate of cancer was 21.7% and 50% (

conclusionsPatients with dysplastic leukoplakia have an increased risk of malignant transformation, but the risk is higher with laryngeal than with oral leukoplakia. There is no significant difference between the groups regarding survival with leukoplakia-associated cancer. Oral patients with no dysplastic lesions have a low risk of malignant transformation. A complete excision and long-term follow up are suggested for high-risk patients to diagnose cancer in an early stage and to control late (over 10 years) malignant events.

Indexed as

oral and laryngeal leukoplakiarisk of malignant transformationsurvival with cancer

Identifiers

PMID37445290
PMCPMC10342278

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.